Myeloma Minute: Happening Today: The Best of 2022 ASCO & EHA


Happening Today: The Best of 2022 ASCO & EHA The Best of 2022 ASCO & EHA: What Patients and Care Partners Need to Know will be happening TODAY at 4 p.m. PST/ 5 p.m. MT/ 6 p.m. CT/ 7 p.m. ET. In this 60-minute webinar, the International Myeloma Foundation (IMF) will be presenting highlights of the recently concluded 2022 American Society of Clinical Oncology (ASCO) Meeting and European Hematology Association (EHA) Congress. At the end of the presentation, participants can ask questions during the Q&A session.


Now Accepting Applications: The 2023 Brian D. Novis Research Grants The Brian D. Novis Research Grant was established in 1995 to honor IMF co-founder Brian D. Novis, who succumbed to multiple myeloma in July 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2023 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for submission of applications is on September 1, 2022.


Video Presentations from Myeloma Experts at ASCO and EHA 2022 Top cancer researchers from across the globe gathered this year for the annual American Society of Clinical Oncology (ASCO) Meeting and European Hematology Association (EHA) Congress. The International Myeloma Foundation (IMF) team is providing these lecture-type video presentations to keep you updated on the latest developments in clinical trials and studies on CAR T-cell therapies, bispecifics, four-drug combination therapies, and more. This is an ongoing event, with more video presentations to be posted. Please check back for updates on the IMF website.


IMF Virtual Regional Community Workshop — South Atlantic States The IMF Regional Community Workshop (RCW) – South Atlantic States will be held on Saturday, July 16 at 10:00 a.m. ET. IMF Senior Director of Regional Community Workshops Kelly Cox will kick off the workshop. Guest speakers include Craig Hofmeister, MD, MPH (Winship Cancer Institute—Atlanta, GA); Ciara Freeman, MD, PhD (Moffit Cancer Center—Tampa, FL); and Nurse Leadership Board (NLB) Member Charise Gleason, MSN, NP-C, AOCNP (Winship Cancer Institute—Atlanta, GA). The workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. NLB Member Charise Gleason will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.


Learn More About the NEWEST Immunotherapy Approved for Myeloma — CARVYKTI™ (ciltacabtagene autoleucel) In February 2022, the FDA approved Carvykti™ for the treatment of adult patients with relapsed or refractory myeloma after four or more prior lines of therapy. Carvykti is a customized immunotherapy (also called “biological therapy”) that uses a patient’s own T cells, which are collected and genetically modified, then infused back into the patient. Carvykti works by recognizing and binding to BCMA, a protein on myeloma cells, leading to the destruction of BCMA-expressing cells, thereby eliminating the myeloma cells. Get your FREE copies of the IMF’s first edition of Understanding CARVYKTI™ (ciltacabtagene autoleucel) and the Carvykti Tip Card in printed form  or  as downloadable PDFs with hyperlinks  to informative  resources.


Explore the IMF’s Mind, Body, and Wellness Website Health and wellness matter to everyone, but it is especially important for myeloma patients and caregivers. Feel better physically and improve emotional and spiritual well-being by participating in a wellness program. The Mind, Body, and Wellness section of the IMF website provides wellness education, movement, exercise, and mindfulness practices tailored for patients and caregivers. Self-advocate for your well-being by beginning your mind and body journey with us.


Shop Amazon Smile for Prime Days and Donate to the IMF Shop on Amazon Prime Days at smile.amazon.com from July 12-13 and designate the International Myeloma Foundation (IMF) as your preferred charity. For every purchase you make, Amazon will donate to the IMF with NO FEES and NO EXTRA COST!


#ASKDRDURIE \| Dr. Durie's Weekly Web Video Series Should patients use mass spectrometry to measure myeloma protein levels?

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Upcoming Events

Donate Now
Laughs 4 Life

Donate Now
George and Julia’s 50th Anniversary

Donate Now
Pieces to A Cure Quilt Raffle

Donate Now
Marnie’s 70th Birthday

Webinar Replays

Watch the Replay
2nd virtual M-Power Charlotte Webinar

Watch the Replay
Living Well with Myeloma — A Promising Future for Treating MM with Bispecific Antibodies

Watch the Replay
Regional Community Workshop — New England

Watch the Replay
IMF Patient & Family Webinar – New Frontiers in Myeloma Care

See also, all of our events.

Happening Today: The Best of 2022 ASCO & EHA

Now Accepting Applications: The 2023 Brian D. Novis Research Grants

Video Presentations from Myeloma Experts at ASCO and EHA 2022

IMF Virtual Regional Community Workshop — South Atlantic States

Learn More About the NEWEST Immunotherapy Approved for Myeloma — CARVYKTI™ (ciltacabtagene autoleucel)

Explore the IMF’s Mind, Body, and Wellness Website

Shop Amazon Smile for Prime Days and Donate to the IMF

#ASKDRDURIE | Dr. Durie's Weekly Web Video Series

Online Patient Forum

Clinical Trial Fact Sheets

Upcoming Events

Webinar Replays

We Thank Our Sponsors: